The Trump administration’s threat of pharmaceutical tariffs could risk significant political backlash, as the drug industry ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at ...

Pfizer Inc. closed 28.57% short of its 52-week high of $31.54, which the company reached on July 30th.

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Fintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Pfizer (NYSE:PFE) with a Neutral ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

Cantor Fitzgerald analyst Carter Gould initiated coverage of Pfizer (PFE) with a Neutral rating and $24 price target Pfizer made “concrete ...

We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...